Literature DB >> 29457552

Reciprocal regulation of YAP/TAZ by the Hippo pathway and the Small GTPase pathway.

Ju-Won Jang1, Min-Kyu Kim1, Suk-Chul Bae1.   

Abstract

Yes-associated protein 1 (YAP) and transcriptional co-activator with PDZ-binding motif (TAZ) (YAP/TAZ) are transcriptional coactivators that regulate genes involved in proliferation and transformation by interacting with DNA-binding transcription factors. Remarkably, YAP/TAZ are essential for cancer initiation or growth of most solid tumors. Their activation induces cancer stem cell attributes, proliferation, and metastasis. The oncogenic activity of YAP/TAZ is inhibited by the Hippo cascade, an evolutionarily conserved pathway that is governed by two kinases, mammalian Ste20-like kinases 1/2 (MST1/2) and Large tumor suppressor kinase 1/2 (LATS1/2), corresponding to Drosophila's Hippo (Hpo) and Warts (Wts), respectively. One of the most influential aspects of YAP/TAZ biology is that these factors are transducers of cell structural features, including polarity, shape, and cytoskeletal organization. In turn, these features are intimately related to the cell's ability to attach to other cells and to the surrounding extracellular matrix (ECM), and are also influenced by the cell's microenvironment. Thus, YAP/TAZ respond to changes that occur at the level of whole tissues. Notably, small GTPases act as master organizers of the actin cytoskeleton. Recent studies provided convincing genetic evidence that small GTPase signaling pathways activate YAP/TAZ, while the Hippo pathway inhibits them. Biochemical studies showed that small GTPases facilitate the YAP-Tea domain transcription factor (TEAD) interaction by inhibiting YAP phosphorylation in response to serum stimulation, while the Hippo pathway facilitates the YAP-RUNX3 interaction by increasing YAP phosphorylation. Therefore, small GTPase pathways activate YAP/TAZ by switching its DNA-binding transcription factors. In this review, we summarize the relationship between the Hippo pathway and small GTPase pathways in the regulation of YAP/TAZ.

Entities:  

Keywords:  Cdc42; Hippo; Rac; Ras; Rho; TAZ; YAP

Mesh:

Substances:

Year:  2018        PMID: 29457552      PMCID: PMC7549623          DOI: 10.1080/21541248.2018.1435986

Source DB:  PubMed          Journal:  Small GTPases        ISSN: 2154-1248


  67 in total

Review 1.  Rho GTPases in cell biology.

Authors:  Sandrine Etienne-Manneville; Alan Hall
Journal:  Nature       Date:  2002-12-12       Impact factor: 49.962

2.  TAZ, a transcriptional modulator of mesenchymal stem cell differentiation.

Authors:  Jeong-Ho Hong; Eun Sook Hwang; Michael T McManus; Adam Amsterdam; Yu Tian; Ralitsa Kalmukova; Elisabetta Mueller; Thomas Benjamin; Bruce M Spiegelman; Phillip A Sharp; Nancy Hopkins; Michael B Yaffe
Journal:  Science       Date:  2005-08-12       Impact factor: 47.728

3.  Yes-associated protein (YAP65) is a proline-rich phosphoprotein that binds to the SH3 domain of the Yes proto-oncogene product.

Authors:  M Sudol
Journal:  Oncogene       Date:  1994-08       Impact factor: 9.867

4.  Requirement of NF-kappaB activation to suppress p53-independent apoptosis induced by oncogenic Ras.

Authors:  M W Mayo; C Y Wang; P C Cogswell; K S Rogers-Graham; S W Lowe; C J Der; A S Baldwin
Journal:  Science       Date:  1997-12-05       Impact factor: 47.728

5.  Elucidation of a universal size-control mechanism in Drosophila and mammals.

Authors:  Jixin Dong; Georg Feldmann; Jianbin Huang; Shian Wu; Nailing Zhang; Sarah A Comerford; Mariana F Gayyed; Robert A Anders; Anirban Maitra; Duojia Pan
Journal:  Cell       Date:  2007-09-21       Impact factor: 41.582

Review 6.  The Hippo pathway and human cancer.

Authors:  Kieran F Harvey; Xiaomeng Zhang; David M Thomas
Journal:  Nat Rev Cancer       Date:  2013-03-07       Impact factor: 60.716

7.  Mutant Gq/11 promote uveal melanoma tumorigenesis by activating YAP.

Authors:  Fa-Xing Yu; Jing Luo; Jung-Soon Mo; Guangbo Liu; Young Chul Kim; Zhipeng Meng; Ling Zhao; Gholam Peyman; Hong Ouyang; Wei Jiang; Jiagang Zhao; Xu Chen; Liangfang Zhang; Cun-Yu Wang; Boris C Bastian; Kang Zhang; Kun-Liang Guan
Journal:  Cancer Cell       Date:  2014-05-29       Impact factor: 31.743

Review 8.  Targeting RAS signalling pathways in cancer therapy.

Authors:  Julian Downward
Journal:  Nat Rev Cancer       Date:  2003-01       Impact factor: 60.716

Review 9.  The hippo signaling pathway in development and cancer.

Authors:  Duojia Pan
Journal:  Dev Cell       Date:  2010-10-19       Impact factor: 12.270

10.  Angiomotins link F-actin architecture to Hippo pathway signaling.

Authors:  Sebastian Mana-Capelli; Murugan Paramasivam; Shubham Dutta; Dannel McCollum
Journal:  Mol Biol Cell       Date:  2014-03-19       Impact factor: 4.138

View more
  7 in total

1.  Pathways Governing Polyethylenimine Polyplex Transfection in Microporous Annealed Particle Scaffolds.

Authors:  Norman F Truong; Sasha Cai Lesher-Pérez; Evan Kurt; Tatiana Segura
Journal:  Bioconjug Chem       Date:  2018-12-18       Impact factor: 4.774

2.  Not the comfy chair! Cancer drugs that act against multiple active sites.

Authors:  Laurence Booth; Andrew Poklepovic; Paul Dent
Journal:  Expert Opin Ther Targets       Date:  2019-11-14       Impact factor: 6.902

3.  Mechanosensitive smooth muscle cell phenotypic plasticity emerging from a null state and the balance between Rac and Rho.

Authors:  Shefali Talwar; Aayush Kant; Tina Xu; Vivek B Shenoy; Richard K Assoian
Journal:  Cell Rep       Date:  2021-04-20       Impact factor: 9.423

4.  Hedgehog signaling is controlled by Rac1 activity.

Authors:  Chao Tang; Ximei Wu; Qianlei Ren; Minli Yao; Shouying Xu; Ziyi Yan
Journal:  Theranostics       Date:  2022-01-01       Impact factor: 11.556

5.  MICAL2 Contributes to Gastric Cancer Cell Proliferation by Promoting YAP Dephosphorylation and Nuclear Translocation.

Authors:  Chenxiang Qi; Pengxiang Min; Qianwen Wang; Yueyuan Wang; Yixuan Song; Yujie Zhang; Maria Bibi; Jun Du
Journal:  Oxid Med Cell Longev       Date:  2021-10-05       Impact factor: 6.543

6.  WNT Signaling Driven by R-spondin 1 and LGR6 in High-grade Serous Ovarian Cancer.

Authors:  Sanghoon Lee; John Jun; William J Kim; Pablo Tamayo; Stephen B Howell
Journal:  Anticancer Res       Date:  2020-11       Impact factor: 2.435

Review 7.  Role of Rho-GTPases in megakaryopoiesis.

Authors:  William Vainchenker; Brahim Arkoun; Francesca Basso-Valentina; Larissa Lordier; Najet Debili; Hana Raslova
Journal:  Small GTPases       Date:  2021-02-11
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.